Hyperfine (NASDAQ:HYPR) Announces Quarterly Earnings Results, Hits Estimates

Hyperfine (NASDAQ:HYPR) released its quarterly earnings data on Tuesday. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09), FiscalAI reports. Hyperfine had a negative return on equity of 98.85% and a negative net margin of 226.88%.The firm had revenue of $3.90 million during the quarter, compared to the consensus estimate of $3.54 million.

Here are the key takeaways from Hyperfine’s conference call:

• Hyperfine posted Q1 2026 revenue of $3.9 million, up 83% year over year, making it the company’s second-highest quarter ever and supported by sales across all three business verticals.
• Gross margin expanded to 50.7%, the third straight quarter above 50%, while net cash burn improved to $8.8 million from $10.1 million a year ago, showing better operating leverage and spending discipline.
• Management reiterated full-year 2026 guidance for $20 million-$22 million in revenue, 50%-55% gross margin, and $26 million-$28 million in cash burn, while saying the business should strengthen through the year.
• The company highlighted several commercial and regulatory milestones, including CE and UKCA marks for the next-generation system and Optive AI software, more than 50% enrollment in the Contrast PMR study, and strong reception to its advanced DWI software.
• Hyperfine sees growth coming from hospitals/IDNs, neurology offices, and international markets, with an expanding pipeline of multi-site IDN deals and plans to launch in Europe in the third quarter; the company also discussed future use in OR and angio-suite settings.

Hyperfine Stock Down 1.6%

Shares of NASDAQ:HYPR traded down $0.03 during midday trading on Thursday, reaching $1.57. The company’s stock had a trading volume of 173,819 shares, compared to its average volume of 537,714. The firm has a market cap of $153.31 million, a price-to-earnings ratio of -3.82 and a beta of 1.42. Hyperfine has a 1 year low of $0.53 and a 1 year high of $2.22. The business has a 50 day moving average price of $1.28 and a 200 day moving average price of $1.15.

Insiders Place Their Bets

In related news, CFO Brett Hale sold 24,188 shares of Hyperfine stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $1.21, for a total value of $29,267.48. Following the transaction, the chief financial officer owned 275,812 shares in the company, valued at approximately $333,732.52. This trade represents a 8.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Thomas Teisseyre sold 24,188 shares of Hyperfine stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $1.21, for a total value of $29,267.48. Following the completion of the transaction, the chief operating officer owned 354,648 shares in the company, valued at $429,124.08. The trade was a 6.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 26.33% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of HYPR. Renaissance Technologies LLC lifted its stake in shares of Hyperfine by 674.4% during the fourth quarter. Renaissance Technologies LLC now owns 364,743 shares of the company’s stock worth $357,000 after purchasing an additional 317,645 shares in the last quarter. Walleye Capital LLC acquired a new position in shares of Hyperfine during the fourth quarter worth about $212,000. Vanguard Group Inc. lifted its stake in shares of Hyperfine by 5.7% during the third quarter. Vanguard Group Inc. now owns 3,511,972 shares of the company’s stock worth $5,092,000 after purchasing an additional 190,136 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Hyperfine by 21.4% during the fourth quarter. Geode Capital Management LLC now owns 815,986 shares of the company’s stock worth $799,000 after purchasing an additional 143,975 shares in the last quarter. Finally, Cerity Partners LLC acquired a new position in shares of Hyperfine during the fourth quarter worth about $59,000. Institutional investors and hedge funds own 15.03% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hyperfine in a research note on Tuesday, April 21st. BTIG Research began coverage on Hyperfine in a research report on Wednesday, April 29th. They set a “buy” rating and a $2.00 price target for the company. Zacks Research raised Hyperfine to a “hold” rating in a research report on Thursday, March 19th. Lake Street Capital raised their price target on Hyperfine from $2.00 to $2.50 and gave the stock a “buy” rating in a research report on Thursday, March 19th. Finally, B. Riley Financial reissued a “buy” rating on shares of Hyperfine in a research report on Wednesday. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Hyperfine presently has a consensus rating of “Hold” and an average price target of $1.59.

About Hyperfine

Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company’s flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.

The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient’s bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients.